Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities who ...

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

The 340B program's “covered entities” serve low-income, poorer populations that tend to be un- or underinsured. Many, if not ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...